Early Initiation of Emicizumab Prophylaxis in Infants With Severe Hemophilia A, a Real-World Experience
BACKGROUND: Intracranial hemorrhage (ICH) is common in infants with hemophilia. We evaluated 15 children with severe hemophilia A who were initiated on emicizumab prophylaxis in infancy at the Pediatric Coagulation Center in Dublin, Ireland. OBSERVATIONS: The median age at emicizumab initiation was 13 weeks (range, 1 to 38 wk), and in 9 children diagnosed in the first week of life, it was 5 weeks (range, 1 to 16 wk). After a median follow-up of 36.3 months (15.6 to 55.75), no child developed ICH or spontaneous bleeding. CONCLUSIONS: Emicizumab prophylaxis in early infancy is safe and effective in the prevention of ICH and spontaneous bleeding in children with severe hemophilia A.
Authors
- Beatrice Nolan (ORCID: https://orcid.org/0000-0003-0145-4736)
- Saad Ahmed (ORCID: https://orcid.org/0000-0003-3389-9078)
Institutions
- University College Dublin (IE)
- Trinity College (CA)
- Trinity College Dublin (IE)
- Children's Health Ireland at Crumlin (IE)
Publication Details
- Journal
- Journal of Pediatric Hematology/Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/mph.0000000000003322
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00